Abstract Body

Background: Mutations at position 148 of HIV integrase (IN) represent a major mutational pathway leading to raltegravir (RAL) and elvitegravir (EVG) resistance. Viruses containing certain Q148 mutation profiles are associated with poor dolutegravir (DTG) treatment responses. In this study, we investigated the effect of Q148H/K/R mutations and other RAL/EVG resistance associated IN mutations on DTG susceptibility using panels of patientderived viruses and site-directed mutants (SDMs). Methodology: Patient-derived viruses (N=210) containing Q148H/K/R mutations were identified by conventional nucleic acid sequencing. SDMs containing Q148H/K/R mutations alone and in combination with one or more additional IN mutations (L74I/M, E92Q, T97A, E138A/D/K/T, G140A/C/S) were constructed. DTG susceptibility was determined using a pseudovirus luciferase reporter assay (PhenoSense HIV Integrase). Results: Patient viruses containing Q148H/K/R mutations displayed reduced DTG susceptibility with a median fold change in IC50 (FC)=4.6 (range 1.7 to 96.0). Q148K viruses that emerge less frequently than Q148H/R variants exhibited larger reductions in DTG susceptibility compared to Q148H/R viruses. All patient viruses contained one or more additional IN mutations with G140 substitutions occurring most frequently followed by E138 substitutions. Based on the analysis of a panel of SDMs, a single mutation at position 148 did not reduce DTG susceptibility (DTG FC=0.5 to 0.7). However, the addition of a second mutation at position 140 conferred measurable reductions in DTG susceptibility (FC=2.2 to 58). The further introduction of additional mutations at positions 74, 92, 97 and 138 conferred incremental reductions in DTG susceptibility. Q148K SDMs containing additional mutations displayed larger reductions in DTG susceptibility than corresponding Q148H/R SDMs, consistent with measurements in patient viruses. Conclusions: In this study, we evaluated a large panel of patient viruses and site-directed mutants to fully characterize the degree of DTG cross resistance that is conferred by Q148K/H/R mutations in combination with additional RAL/EVG resistance associated mutations.